Dexlansoprazole
Dexlansoprazole structure
|
Common Name | Dexlansoprazole | ||
|---|---|---|---|---|
| CAS Number | 138530-94-6 | Molecular Weight | 369.362 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 555.8±60.0 °C at 760 mmHg | |
| Molecular Formula | C16H14F3N3O2S | Melting Point | 66-68?C | |
| MSDS | N/A | Flash Point | 289.9±32.9 °C | |
Use of Dexlansoprazole(R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Target: Proton PumpLansoprazole sodium is sodium salt form of lansoprazole, lansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h [1]. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups [2]. lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole [3]. |
| Name | R-(+)-Lansoprazole |
|---|---|
| Synonym | More Synonyms |
| Description | (R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Target: Proton PumpLansoprazole sodium is sodium salt form of lansoprazole, lansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h [1]. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups [2]. lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 555.8±60.0 °C at 760 mmHg |
| Melting Point | 66-68?C |
| Molecular Formula | C16H14F3N3O2S |
| Molecular Weight | 369.362 |
| Flash Point | 289.9±32.9 °C |
| Exact Mass | 369.075867 |
| PSA | 87.08000 |
| LogP | 2.76 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.635 |
| InChIKey | MJIHNNLFOKEZEW-RUZDIDTESA-N |
| SMILES | Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1 |
| Storage condition | Refrigerator |
| Hazard Codes | Xi |
|---|
|
~%
Dexlansoprazole CAS#:138530-94-6 |
| Literature: WO2010/95144 A2, ; Page/Page column 22 ; |
|
~58%
Dexlansoprazole CAS#:138530-94-6 |
| Literature: Del Rio; Wang; Achab; Bohe Organic Letters, 2007 , vol. 9, # 12 p. 2265 - 2268 |
|
~%
Dexlansoprazole CAS#:138530-94-6 |
| Literature: WO2009/87672 A1, ; Page/Page column 6-8 ; |
|
~%
Dexlansoprazole CAS#:138530-94-6 |
| Literature: Tetrahedron Asymmetry, , vol. 14, # 4 p. 407 - 410 |
|
~%
Dexlansoprazole CAS#:138530-94-6 |
| Literature: Tetrahedron Letters, , vol. 52, # 42 p. 5464 - 5466 |
|
~%
Dexlansoprazole CAS#:138530-94-6 |
| Literature: Chirality, , vol. 22, # 1 p. 35 - 41 |
![N-camphorsulfonyl-2-[(R)-[[3-methyl-4-(2,2,2-trifIuoroethoxy)-2-pyridinyl]methyl]sulphinyl]-1H-benzimidazole structure](https://image.chemsrc.com/caspic/082/1240684-26-7.png)
![2-[[(4-Nitro-3-Methyl-2-Pyridinyl)-2-Methyl]Thio]-1H-Benzimidazole structure](https://image.chemsrc.com/caspic/298/152402-98-7.png)
| Dexlansoprazole |
| 1H-Benzimidazole, 2-[(R)-[(1R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- |
| (R)-2-(3-N,N-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenoxyisobutyrate |
| 2-[(R)-{[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl}sulfinyl]-1H-benzimidazole |
| R-(+)-Lansoprazole |
| (+)-Lansoprazole |
| Dexilant |
| FESO |
| (R)-lansoprazole |
| Kapidex |
| R-lansoprazole |
| Lansoprazole Impurity 14 |